618 related articles for article (PubMed ID: 17070588)
1. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
Wilson SE; Perry HD
Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
Rao SN; Rao RD
Cornea; 2006 Jul; 25(6):674-8. PubMed ID: 17077659
[TBL] [Abstract][Full Text] [Related]
3. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
Salib GM; McDonald MB; Smolek M
J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
[TBL] [Abstract][Full Text] [Related]
5. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
[TBL] [Abstract][Full Text] [Related]
6. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD; Pflugfelder SC; Tauber J; Foulks GN
Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
[TBL] [Abstract][Full Text] [Related]
7. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
Rao SN
J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
[TBL] [Abstract][Full Text] [Related]
8. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
9. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.
Marsh P; Pflugfelder SC
Ophthalmology; 1999 Apr; 106(4):811-6. PubMed ID: 10201607
[TBL] [Abstract][Full Text] [Related]
10. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye.
Roberts CW; Carniglia PE; Brazzo BG
Cornea; 2007 Aug; 26(7):805-9. PubMed ID: 17667613
[TBL] [Abstract][Full Text] [Related]
11. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.
Cordero-Coma M; Anzaar F; Sobrin L; Foster CS
Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic implications of topical cyclosporin A for the treatment of dry eye.
Cross WD; Lay LF; Walt JG; Kozma CM
Manag Care Interface; 2002 Sep; 15(9):44-9. PubMed ID: 12244650
[TBL] [Abstract][Full Text] [Related]
13. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
Kujawa A; Rózycki R
Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
[TBL] [Abstract][Full Text] [Related]
14. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.
Sullivan BD; Crews LA; Sönmez B; de la Paz MF; Comert E; Charoenrook V; de Araujo AL; Pepose JS; Berg MS; Kosheleff VP; Lemp MA
Cornea; 2012 Sep; 31(9):1000-8. PubMed ID: 22475641
[TBL] [Abstract][Full Text] [Related]
16. Topical cyclosporine-A in dry eye associated with chronic graft versus host disease.
Kurt RA; Yalçindag N; Atilla H; Arat M
Ann Ophthalmol (Skokie); 2009; 41(3-4):166-9. PubMed ID: 20214049
[TBL] [Abstract][Full Text] [Related]
17. Occult thyroid eye disease in patients presenting with dry eye symptoms.
Gupta A; Sadeghi PB; Akpek EK
Am J Ophthalmol; 2009 May; 147(5):919-23. PubMed ID: 19211095
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease.
Hardten DR; Brown MJ; Pham-Vang S
Curr Med Res Opin; 2007 Sep; 23(9):2083-91. PubMed ID: 17822610
[TBL] [Abstract][Full Text] [Related]
19. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
[TBL] [Abstract][Full Text] [Related]
20. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
Kim EC; Choi JS; Joo CK
Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
